tetano
Editor, Senior Moderator
J Infect Dis. 2015 Feb 23. pii: jiv099. [Epub ahead of print]
[h=1]Impact of adjuvants on the immunogenicity and efficacy of split-virion H7N9 vaccine in ferrets.[/h] Wong SS[SUP]1[/SUP], Kaplan B[SUP]1[/SUP], Zanin M[SUP]1[/SUP], Debeauchamp J[SUP]1[/SUP], Kercher L[SUP]2[/SUP], Crumpton JC[SUP]1[/SUP], Seiler P[SUP]1[/SUP], Sun Y[SUP]3[/SUP], Tang L[SUP]3[/SUP], Krauss S[SUP]1[/SUP], Webster R[SUP]1[/SUP], Webby RJ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] An effective vaccine is urgently needed against the H7N9 avian influenza virus. Here, we evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with or without the oil-in-water adjuvants in ferrets.
[h=4]METHODS:[/h] Ferrets were vaccinated with two doses of unadjuvanted, MF59 or AS03-adjuvanted A/Shanghai/2/2013 (H7N9) vaccine and the induction of antibodies to hemagglutinin (HA) or neuraminidase (NA) proteins were evaluated. Ferrets were then challenged with wild-type H7N9 virus to assess the vaccine's protective efficacy. The vaccine composition and integrity was also evaluated in vitro.
[h=4]RESULTS:[/h] Adjuvanted-vaccines stimulated robust serum antibody titers against HA and NA compared to the unadjuvanted vaccines. Although there was a difference in adjuvanticity between AS03 and MF59 at a lower dose (3.75 ?g of HA), both adjuvants induced comparable antibody responses after two doses of 15 ?g. Upon challenge, ferrets that received adjuvanted vaccines showed lower viral burden than the control or unadjuvanted vaccine group. In vitro examinations revealed that the vaccine contained visible split-virus particles and retained the native conformation of HA recognizable by polyclonal and monoclonal antibodies.
[h=4]CONCLUSIONS:[/h] The adjuvanted-H7N9 vaccines demonstrated superior immunogenicity and protective efficacy against H7N9 infection in ferrets and hold potential as a vaccination regimen.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 25712975 [PubMed - as supplied by publisher]
[h=1]Impact of adjuvants on the immunogenicity and efficacy of split-virion H7N9 vaccine in ferrets.[/h] Wong SS[SUP]1[/SUP], Kaplan B[SUP]1[/SUP], Zanin M[SUP]1[/SUP], Debeauchamp J[SUP]1[/SUP], Kercher L[SUP]2[/SUP], Crumpton JC[SUP]1[/SUP], Seiler P[SUP]1[/SUP], Sun Y[SUP]3[/SUP], Tang L[SUP]3[/SUP], Krauss S[SUP]1[/SUP], Webster R[SUP]1[/SUP], Webby RJ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] An effective vaccine is urgently needed against the H7N9 avian influenza virus. Here, we evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with or without the oil-in-water adjuvants in ferrets.
[h=4]METHODS:[/h] Ferrets were vaccinated with two doses of unadjuvanted, MF59 or AS03-adjuvanted A/Shanghai/2/2013 (H7N9) vaccine and the induction of antibodies to hemagglutinin (HA) or neuraminidase (NA) proteins were evaluated. Ferrets were then challenged with wild-type H7N9 virus to assess the vaccine's protective efficacy. The vaccine composition and integrity was also evaluated in vitro.
[h=4]RESULTS:[/h] Adjuvanted-vaccines stimulated robust serum antibody titers against HA and NA compared to the unadjuvanted vaccines. Although there was a difference in adjuvanticity between AS03 and MF59 at a lower dose (3.75 ?g of HA), both adjuvants induced comparable antibody responses after two doses of 15 ?g. Upon challenge, ferrets that received adjuvanted vaccines showed lower viral burden than the control or unadjuvanted vaccine group. In vitro examinations revealed that the vaccine contained visible split-virus particles and retained the native conformation of HA recognizable by polyclonal and monoclonal antibodies.
[h=4]CONCLUSIONS:[/h] The adjuvanted-H7N9 vaccines demonstrated superior immunogenicity and protective efficacy against H7N9 infection in ferrets and hold potential as a vaccination regimen.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 25712975 [PubMed - as supplied by publisher]